Phase I trial of combined chemotherapy of bevacizumab, panitumumab and irinotecan as 3rd-line chemotherapy in chmotherapy-refractory metastatic colorectal cancer.

ABSTRACT: Interventions: Combined chemotherapy of bevacizumab, panitumumab, irinotecan. Primary outcome(s): Proportion of dose limiting toxicity (DLT). Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2624760 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR